Commercial A year after Vertex’s big launch, pain drug research faces a pivotal moment BioPharma DiveJournavx revived an area of development long considered a graveyard.Pain & AnaesthesiaRead full story pharminent May 12, 2026 (Last updated: May 16, 2026) BioPharma Dive Journavx revived an area of development long considered a graveyard. Pain & Anaesthesia Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA weighs drug repurposing pathway for underserved diseasesNext: Novo says high-dose Wegovy can cause 28% weight loss Related Stories Commercial Lilly UK recruits ex-England cricketer as obesity champion pharminent May 15, 2026 Commercial Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls pharminent May 11, 2026 Commercial Novo’s CEO champions “record-breaking start” for Wegovy pill in US market pharminent May 8, 2026
